Conversely, ARID1A loss may increase the risk for steatohepatitis and cancer progression by altering immunity in vivo [27] or tumorigenesis by activating angiopoietin-2 (ANGPT2) transcription in vitro and causing angiogenesis in vivo [28]. This evidence concerns the gene ANGPT2 and cancer.